SetPoint Medical is committed to evidence-based advancement of treatment options for chronic autoimmune diseases through robust clinical research.
SetPoint Medical Appoints Amy Derosier as Vice President of Clinical Affairs
SetPoint Medical, a clinical-stage bioelectronic medicine company developing therapies for chronic autoimmune diseases, today announced the appointment of Amy Derosier as Vice President of Clinical Affairs. “Amy’s extensive experience in successfully designing and executing clinical trials for novel medical devices complements that of our CMO, Dr. David Chernoff, who has extensive experience in rheumatology clinical research. Her leadership and partnership with Dr. Chernoff will be invaluable as we...
The Lancet Rheumatology Publishes Clinical Trial Data Demonstrating Promising Safety and Efficacy Profile for a Novel Bioelectronic Device in patients with Drug Refractory Rheumatoid Arthritis
Device reduced disease activity in 50% of patients who had failed multiple drug classes including Janus Kinase Inhibitors (JAKi) SetPoint Medical, Inc. today announced that data from a first-in-human pilot trial that evaluated its proprietary Vagus Nerve Stimulation (VNS) microregulator in a cohort of patients with multi-drug refractory rheumatoid arthritis (RA) were published in The Lancet Rheumatology. The study found the bioelectronic device reduced signs and symptoms of disease in 50% of the treated...
No reviews were found for Cutting-Edge Research Services. Be the first to review!